Telbivudine in Adults Previously Treated in Idenix-Sponsored Telbivudine Studies
Public ClinicalTrials.gov record NCT00142298. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open Label Trial of Telbivudine (LdT) in Adults With Chronic Hepatitis B Previously Treated in Idenix-Sponsored Telbivudine Studies
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This trial is being conducted as an open-label, extended-term study for patients with chronic hepatitis B who have previously completed an Idenix-sponsored trial with telbivudine.
Study identification
- NCT ID
- NCT00142298
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 1,869 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 16 Years to 70 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 28, 2005
- Primary completion
- Oct 31, 2009
- Completion
- Oct 31, 2009
- Last update posted
- Aug 20, 2020
2005 – 2009
United States locations
- U.S. sites
- 19
- U.S. states
- 14
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Novartis Investigational Site | Phoenix | Arizona | 85001 | — |
| Novartis Investigational Site | Los Angeles | California | 90001 | — |
| Novartis Investigational Site | Los Angeles | California | 90073 | — |
| Novartis Investigational Site | Pasadena | California | 91103 | — |
| Novartis Investigational Site | Sacramento | California | — | — |
| Novartis Investigational Site | San Diego | California | 91945 | — |
| Novartis Investigational Site | San Francisco | California | 94115 | — |
| Novartis Investigational Site | Sarasota | Florida | — | — |
| Novartis Investigational Site | Atlanta | Georgia | — | — |
| Novartis Investigational Site | Honolulu | Hawaii | 96812 | — |
| Novartis Investigational Site | Chicago | Illinois | 60176 | — |
| Novartis Investigational Site | Boston | Massachusetts | 02215 | — |
| Novartis Investigational Site | Ann Arbor | Michigan | 48104 | — |
| Novartis Investigational Site | St Louis | Missouri | 63143 | — |
| Novartis Investigational Site | New York | New York | 10029 | — |
| Novartis Investigational Site | Chapel Hill | North Carolina | 27599-7211 | — |
| Novartis Investigational Site | Philadelphia | Pennsylvania | 19103 | — |
| Novartis Investigational Site | Houston | Texas | 77007 | — |
| Novartis Investigational Site | Richmond | Virginia | 23220 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 20 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00142298, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 20, 2020 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00142298 live on ClinicalTrials.gov.